文献速递神经肿瘤

原发性与挽救性立体定向放射外科治疗嗅沟脑膜瘤:35年单中心经验

Primary Versus Salvage Stereotactic Radiosurgery for Patients With Olfactory Groove Meningiomas: A 35-Year Single-Institution Experience.
PubMed 文献 · Neurosurgery · 2025-09-29

中位肿瘤体积4.30 cc,中位边缘剂量13 Gy。原发性SRS的局部肿瘤控制(LTC)优于挽救性SRS,且多数患者嗅觉功能得以保留或改善;既往切除与嗅觉丧失及LTC下降相关。

要点

  • 原发性SRS局部肿瘤控制优于挽救性SRS(进展率8.33% vs 22.5%)。
  • 既往切除与嗅觉丧失(P<.01)及局部肿瘤控制下降(P=.024)相关。
  • SRS后多数原发性患者症状改善(73%),而挽救性SRS仅23%改善。

核心结论

  • SRS为OGM患者提供低风险的长期肿瘤控制,原发性SRS的LTC及嗅觉功能保留或改善优于挽救性SRS。

研究设计与样本

  • 中位年龄62岁(范围33-90岁),48例(60.76%)原发性SRS,31例(39.24%)既往切除后挽救性SRS。
  • 中位肿瘤体积4.30 cc(范围0.19-26.90 cc),中位边缘剂量13 Gy(范围9-18 Gy)。

主要发现

  • 全部OGM患者总生存期为17年(范围0.8-24.3年),无患者死于颅内肿瘤进展。
  • 原发性SRS组48例中4例(8.33%)在中位9.2年(范围0.4-12.3年)出现肿瘤进展。
  • 挽救性SRS组31例中7例(22.5%)在中位6.4年(范围0.4-15.2年)出现延迟肿瘤进展。
  • 既往切除与嗅觉丧失(P<.01)及LTC下降(P=.024)相关。
  • 原发性SRS后73%患者症状改善,挽救性SRS后23%患者临床改善;SRS时有瘤周水肿者中位水肿体积减少82%。

关键数值与推荐

  • 原发性SRS肿瘤进展率8.33%,挽救性SRS为22.5%。
  • 既往切除与嗅觉丧失相关(P<.01),与LTC下降相关(P=.024)。
  • 原发性SRS后症状改善率73%,挽救性SRS后临床改善率23%。
  • SRS时有瘤周水肿者中位水肿体积减少82%。
  • 中位边缘剂量13 Gy(范围9-18 Gy),中位肿瘤体积4.30 cc(范围0.19-26.90 cc)。

临床怎么用

  • 对于OGM患者,原发性SRS可提供优于挽救性SRS的长期局部肿瘤控制和嗅觉功能保护。
  • 既往切除史与嗅觉丧失及LTC下降相关,选择 salvage SRS 时需权衡此风险。
  • SRS对瘤周水肿有显著缩小作用,可用于伴有水肿的OGM患者管理。

局限性

  • 随访时间范围较宽(0.8-24.3年),部分患者随访时长不一。
  • 未报告SRS具体方案细节及不良反应的全面数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Stereotactic radiosurgery (SRS) is an important management strategy for patients with olfactory groove meningiomas (OGMs). This study aimed to compare outcomes after primary SRS vs salvage SRS postresection in our institution over the past 35 years. METHODS: We reviewed the radiographic imaging of 2030 patients with meningiomas who underwent SRS between 1987 and 2022. Seventy-nine patients with OGM were identified. The median patient age at SRS was 62 years (range, 33-90 years). Forty-eight patients (60.76%) underwent primary SRS and 31 patients (39.24%) had previous resections. The median tumor volume was 4.30 cc (range, 0.19-26.90 cc), and the median margin dose prescribed at SRS was 13 Gy (range, 9-18 Gy). SRS protocol, neurological outcomes, overall survival, and local tumor control (LTC) were evaluated. RESULTS: The overall survival for all OGM patients was 17 years (range, 0.8-24.3 years). No patient deaths were related to intracranial tumor progression. Among primary SRS in 48 patients, 4 (8.33%) had tumor progression at a median time of 9.2 years (range, 0.4-12.3 years). For patients who underwent salvage SRS, 7 patients (22.5%) had delayed tumor progression at a median time of 6.4 years (range, 0.4-15.2 years) after SRS. Previous resection was found to be associated with anosmia ( P < .01) and decreased LTC ( P = .024). After primary SRS, 73% of patients experienced symptom improvement change. After salvage SRS 23 % of patients showed clinical improvement. In patients with peritumoral edema at SRS, the median percentage edema volume reduction was 82% after SRS. CONCLUSION: SRS provided low risk long-term tumor control in OGM patients. Primary SRS provided superior LTC and preservation or improvement of olfactory function in most patients.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Wei CZ, Shanahan RM, Scanlon S, et al. Primary Versus Salvage Stereotactic Radiosurgery for Patients With Olfactory Groove Meningiomas: A 35-Year Single-Institution Experience. Neurosurgery. 2025. PMID: 41020603. doi:10.1227/neu.0000000000003759

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。